Madrigal Pharmaceuticals (MDGL) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Madrigal Pharmaceuticals, Inc.

MDGL•Nasdaq Stock Market•Healthcare•Biotechnology

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)

CurrencyUSD - USD

TypeStock

SubtypeCommon Stock

Contact Information

Websitewww.madrigalpharma.com

Phone267 824 2827

Address

Four Tower Bridge, 200 Barr Harbor Drive West Conshohocken, Pennsylvania 19428 United States

Corporate Identifiers

CIK0001157601

CUSIP558868105

ISINUS5588681057

SIC2834

Leadership Team & Key Executives

William J. Sibold

Chief Executive Officer, President and Director

Dr. Rebecca A. Taub M.D.

Founder, Senior Scientific and Medical Advisor and Director

Mardi C. Dier

Executive Vice President and Chief Financial Officer

Shannon Kelley

Executive Vice President, Chief Legal Officer and Corporate Secretary

Carole Huntsman

Executive Vice President and Chief Commercial Officer

Dr. David Soergel M.D.

Executive Vice President and Chief Medical Officer

Mark Underwood

Executive Vice President of Business Planning and Operations

Rita Thakkar

Senior Vice President and Chief Accounting Officer

Ronald Filippo

Executive Vice President and Chief Information Officer

Tina E. Ventura

Chief Investor Relations Officer

About Madrigal Pharmaceuticals

Company Information

Stock Details

Contact Information

Corporate Identifiers

Leadership Team & Key Executives